Dynavax Technologies Corp. believes Heplisav-B labeling that is favorable on efficacy and neutral on safety should allow it to extract greater value from any potential commercial partnership on the hepatitis B vaccine in the US.
Heplisav-B Approval Has Dynavax Going It Alone On US Launch In Early 2018
Hepatitis B vaccine's favorable efficacy data relative to GSK's Engerix-B and neutral safety language mean that any partnership opportunity 'would need to be a highly attractive one to alter our current course,' Dynavax CEO Gray says.
